The IBTA’s monthly e-News has been released and has emailed to all subscribers. Emailed to over 5,000 people around the globe, including clinicians, patients, researchers and others, it gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
This month’s highlights
You can read the IBTA e-News March 2023 edition in full online here.
Some highlights from this month’s round-up:
- Results from the international phase 3 INDIGO trial (NCT04164901) published in The New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Clinical Oncology (ASCO) have shown that an oral drug called vorasidenib, which inhibits IDH1 and IDH2 enzymes, significantly lengthens the time until tumour progression and the need for further treatment in patients with grade 2 IDH-mutant glioma compared to placebo.
- A study published in Cancer investigating the outcomes of glioblastoma patients from different racial, social and economic groups in a single cancer centre in Alabama, US, has found that African American patients had better survival than white patients, even after controlling for molecular and treatment factors. The study’s authors suggest that there might be a genetic advantage for African American patients with glioblastoma, but more research is needed to confirm this finding.
- A study published in JAMA Oncology that analysed the records of 404 patients with brain metastases (tumours spread from elsewhere in the body) from across several institutions has found that outcomes are better when stereotactic radiosurgery was given before, rather than after surgery.
- A phase 1/2 clinical trial (DART) of a drug called Deflexifol® in refractory and relapsed childhood brain tumours, including ependymoma is due to begin at paediatric oncology sites in Australia, starting in Sydney Children’s Hospital, New South Wales, according to an announcement from the institution.
- IN8bio has announced updated data from an ongoing Phase 1 clinical trial (NCT04165941) of INB-200 in patients with newly diagnosed glioblastoma. The update was presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, demonstrating that the treatment has manageable toxicity and is showing encouraging progression-free survival, with two patients remaining progression free at 18.9 and 14.8 months.
- Day One Biopharmaceuticals has announced that new data has been released at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting from the registrational phase 2 FIREFLY-1 trial (NCT04775485) evaluating the investigational agent tovorafenib (DAY101). FIREFLY-1 is evaluating tovorafenib as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive paediatric low-grade glioma with a known activating BRAF alteration.
To see an archive of existing e-News issues, click here.
Sign up to receive the e-News every month by registering here.
